India Proposes OTC List In Draft Rule Lacking Clarity On Pricing, Switching Pathway
Executive Summary
India puts out rules for first set of over-the-counter drugs but provides no specifics on the pricing policy for such products or the wider switching pathway. Can the framework foster responsible self-medication and help reap value for patients in a market where the oversight of trade channels for sale of prescription-based drugs is lax?
You may also be interested in...
Bayer Extends Afrin Line With First OTC Oxymetazoline Spray In US For Children Under 6
Children’s Afrin regular and no-drip formulations reach US stores with consumers having choices between dozens of oxymetazoline nasal sprays available under an FDA OTC monograph. But products indicated for children was limited to one, Mucinex Childrens Stuffy Nose, and it’s for children 6 and up.
Providing High Value, OTC Drugs Deserve Higher Profile In Health Care – CHPA
While Rx drug pricing is under attack by Congress, White House and consumer and public health advocacy groups, OTC drugs' value isn't gaining a higher profile. "Our health care system undervalues the contribution of our industry's products," says CHPA chief Scott Melville. Trade group conducts “Value of OTC Medicines" study for reasons including raising the profile of consumer health products in the US health care system.
Can Modicare Reshape India’s Health Care Paradigm?
India’s new government-funded health care program expects to expand access to treatment to more than 100 million families. Can it effectively deliver on its promise and also materially expand opportunities for hospitals and pharma?